334 related articles for article (PubMed ID: 17329446)
1. Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.
Tedeschi R; Pin E; Martorelli D; Bidoli E; Marus A; Pratesi C; Bortolin MT; Zanussi S; Vaccher E; Dolcetti R; De Paoli P
Clin Vaccine Immunol; 2007 Apr; 14(4):435-41. PubMed ID: 17329446
[TBL] [Abstract][Full Text] [Related]
2. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.
Fachiroh J; Schouten T; Hariwiyanto B; Paramita DK; Harijadi A; Haryana SM; Ng MH; Middeldorp JM
J Infect Dis; 2004 Jul; 190(1):53-62. PubMed ID: 15195243
[TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China.
He YQ; Xue WQ; Xu FH; Xu YF; Zhang JB; Yu HL; Feng QS; Chen LZ; Cao SM; Liu Q; Mu J; Zeng YX; Jia WH
EBioMedicine; 2018 Apr; 30():184-191. PubMed ID: 29606628
[TBL] [Abstract][Full Text] [Related]
4. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Xia C; Zhu K; Zheng G
Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
[TBL] [Abstract][Full Text] [Related]
5. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
[TBL] [Abstract][Full Text] [Related]
8. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
9. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
[TBL] [Abstract][Full Text] [Related]
11. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
12. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
[TBL] [Abstract][Full Text] [Related]
13. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
14. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.
Paramita DK; Fatmawati C; Juwana H; van Schaijk FG; Fachiroh J; Haryana SM; Middeldorp JM
J Med Virol; 2011 Apr; 83(4):665-78. PubMed ID: 21328382
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of the Epstein-Barr virus serological markers in patients with nasopharyngeal carcinoma in cases of undetectable primary tumor location.
Gurtsevitch VE; Senyuta NB; Lomaya MV; Ignatova AV; Dushenkina TE; Repkina IA; Pavlovskaya AI; Mudunov AM
Vopr Virusol; 2016; 61(5):205-12. PubMed ID: 29323852
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma.
Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
19. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels.
Guo X; Li T; Li F; Xu Y; Wang H; Cheng W; Tang J; Zhou G; Chen H; Ng M; Ji M; Ge S; Xia N
Oral Oncol; 2019 Jun; 93():85-90. PubMed ID: 31109701
[TBL] [Abstract][Full Text] [Related]
20. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]